Incyte Corp. Stock Rating Upgraded by Barclays (INCY)
Incyte Corp. (NASDAQ:INCY) was upgraded by equities researchers at Barclays to an “overweight” rating in a research report issued on Friday, Stock Ratings News reports. The firm currently has a $64.00 target price on the stock, up from their previous target price of $36.00. Barclays’ price target points to a potential upside of 13.94% from the company’s current price.
INCY has been the subject of a number of other recent research reports. Analysts at Nomura initiated coverage on shares of Incyte Corp. in a research note to investors on Wednesday. They set a “buy” rating and a $68.00 price target on the stock. Separately, analysts at UBS AG reiterated a “buy” rating on shares of Incyte Corp. in a research note to investors on Monday. They now have a $74.00 price target on the stock, up previously from $47.00. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Incyte Corp. in a research note to investors on Monday. They now have a $55.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and fifteen have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $50.27.
Shares of Incyte Corp. (NASDAQ:INCY) opened at 56.17 on Friday. Incyte Corp. has a 52 week low of $17.44 and a 52 week high of $56.26. The stock has a 50-day moving average of $49.27 and a 200-day moving average of $36.65. The company’s market cap is $9.050 billion.
Incyte Corp. (NASDAQ:INCY) last released its earnings data on Thursday, October 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.01. The company had revenue of $85.10 million for the quarter, compared to the consensus estimate of $81.40 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The company’s revenue for the quarter was up 40.7% on a year-over-year basis. Analysts expect that Incyte Corp. will post $-0.44 EPS for the current fiscal year.
Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.